India is in a prime position to benefit from the growing biopharma acquisition trend, which is being driven by a global genomics revolution and an impending $300 billion patent expiration wave.

According to the Vallum Capital report, India has more WHO-certified pharmaceutical manufacturing facilities than any other nation in the world, and for three decades, the approach has been consistent: science developed in the West, scaled and supplied by India.

Indian producers will have their best growth opportunities due to the massive wave of patent expirations, and the medications that are set to expire include biologics, gene treatments, and precision oncology drugs rather than small molecules.

The report stated that India is enhancing its capabilities in these areas with programs like the Biopharma Shakti scheme and the Genome India Project, which maps 10,000 genomes across 99 ethnic groupings.

The firm stated that India’s domestic genomics market is growing at over 16% annually and is working hard to prepare for this period.

Artificial intelligence is shortening the time it takes to find new drugs from ten years to less than 18 months, and machine learning and clinical genomic data are generating commercial income that supports faster development.

Companies in the genomics industry are now using clinical genomic data to accelerate target identification at a scale that no conventional research institution can match.

Using machine learning, certain platforms are conducting more than a million biological trials every week.

Biopharma M&A totaled $106 billion across 201 transactions in the first six months of 2026 alone, putting it on track for its best full year since before the pandemic.

Biotech IPOs in the first half of 2026 brought in more money than the whole industry did in all of 2025, a year in which just 11 companies made their global debut. In 2025, venture capital spent in biotech increased by 28% year over year, reaching $38 billion.